Evenamide 15 mg bid for schizophrenia, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Sep 2025: Trial registered, NCT07184619
  2. 23 Jan 2026: Trial started, NCT07184619

The trials

NCT07184619: Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

State
Under way
Phase
Phase 3
People
400 planned
Started
23 Jan 2026
Primary completion
31 Mar 2027
Arms
Evenamide 15 mg bid
Results
None posted
  1. 22 Sep 2025: Trial registered
  2. 23 Jan 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.